BSV DEAL
![Mankind Pharma eyes ?9,000 cr via debt to stitch BSV deal](https://img.etimg.com/thumb/msid-113003182,width-100,height-75,resizemode-4/industry/healthcare/biotech/pharmaceuticals/mankind-pharma-eyes-9000-cr-via-debt-to-stitch-bsv-deal.jpg)
Mankind Pharma eyes ?9,000 cr via debt to stitch BSV deal
The average blended cost of the debt is likely to be around 8.50% with the firm seeking to borrow money over one- to-five years, said three people familiar with the plans. "Bankers have already approached large mutual funds to place the debt, which will range from one year and may go up to five years looking at the demand," said one of the persons.
![Best Serums for Summer in India to Protect And Rejuvenate Your Face](https://img.etimg.com/thumb/msid-109534042,width-100,height-75,resizemode-4/top-trending-products/beauty/skin-care/best-serums-for-summer-in-india-to-protect-and-rejuvenate-your-face.jpg)
Best Serums for Summer in India to Protect And Rejuvenate Your Face
Are you looking for serum for yourself to help your skin feel better during the upcoming hot summer? If so, then continue reading this article to learn about the best serums for summer in India. All of these options are available on Amazon and you can place your order using the buying link shared in the article below.
![Torrent, Zydus, EQT set to make the cut for $3 bn JB Chemicals buyout](https://img.etimg.com/thumb/msid-112355817,width-100,height-75,resizemode-4/industry/healthcare/biotech/pharmaceuticals/torrent-zydus-eqt-set-to-make-the-cut-for-3-bn-jb-chemicals-buyout.jpg)
Torrent, Zydus, EQT set to make the cut for $3 bn JB Chemicals buyout
Torrent Pharma and Zydus Lifesciences are vying to acquire JB Chemicals and Pharmaceuticals, with both firms shortlisted by KKR, the current owner. Torrent has started discussions with banks for financing, while private equity firm EQT is also expected to participate. Dr. Reddy’s Laboratories has shown interest but has yet to submit an offer.
![Mankind Pharma shares drop 2% despite 10% YoY Q1 PAT growth. Buy, sell, or hold?](https://img.etimg.com/thumb/msid-112191587,width-100,height-75,resizemode-4/markets/stocks/news/mankind-pharma-shares-drop-2-despite-10-yoy-q1-pat-growth-buy-sell-or-hold.jpg)
Mankind Pharma shares drop 2% despite 10% YoY Q1 PAT growth. Buy, sell, or hold?
Mankind Pharma's shares fell 2% to Rs 1,985.50, despite the company announcing a 10% YoY rise in net profit to Rs 543 crore for the first quarter of FY25. Revenues increased 12% YoY to Rs 2,893 crore. Brokerages had mixed reactions, with Macquarie, Motilal Oswal, and Kotak Equities offering varied recommendations.
![Be a bit cautious in auto stocks and do not chase the particular rally in Maruti: Dipan Mehta](https://img.etimg.com/thumb/msid-112168401,width-100,height-75,resizemode-4/markets/expert-view/be-a-bit-cautious-in-auto-stocks-and-do-not-chase-the-particular-rally-in-maruti-dipan-mehta.jpg)
Be a bit cautious in auto stocks and do not chase the particular rally in Maruti: Dipan Mehta
Dipan Mehta of Elixir Equities discussed the outlook for the auto and cement industries, noting potential slowdowns and increased competition. He commented on recent developments in speculative trading regulations, the pharma sector, and the performance of companies like Zomato, Paytm, and Maruti. Mehta advised caution in the auto sector while expressing optimism about select pharma stocks.
![Market not much enthused by Mankind's BSV buy](https://img.etimg.com/thumb/msid-112092896,width-100,height-75,resizemode-4/markets/stocks/news/market-not-much-enthused-by-mankinds-bsv-buy.jpg)
Market not much enthused by Mankind's BSV buy
After initially cheering the deal, the stock market gave its thumbs-down to Mankind acquiring BSV at the premium valuations of eight times its FY24 revenues and 23 times its estimated ebitda of FY25. The Mankind stock opened 4.5% higher on Friday but closed 3.6% lower. Worries over funding of expensive deal and taking of debt for a debt-free company dragged down the positive sentiment.
- Go To Page 1
Mankind to use debt, internal accruals to fund BSV buyout
Mankind Pharma announced a ?13,630 crore acquisition of Bharat Serums and Vaccines (BSV) to be funded through internal accruals and a mix of debt and equity. This strategic move will make them leaders in the gynaecology-fertility segment. The acquisition aligns with their goal to expand in high-potential areas and is expected to boost earnings from the second year.
Mankind trumps EQT-ADIA to buy BSV for $1.67 bn
This is the largest acquisition by Mankind Pharma, India’s 4th largest pharma company by market share. A formal announcement regarding the deal is likely by this week.
10 Best Soundbars in India 2024
Looking to buy a great soundbar? This article lists some of the best-performing and highest-rated soundbars on the market with a detailed index of the variants and their price along with specifications. Even if it is the quality sound experience you’re searching for on a budget, we have the best suggestions for you.
Mankind Pharma in race with PEs to buy BSV Group at possible valuation of Rs 13,000 crore
Warburg Pincus, ChrysCapital, TPG, Blackstone, EQT, Mankind Pharma, and Dr Reddy's Laboratories are competing to acquire BSV Group, a biopharma firm specializing in women's health and critical care products, indicating a trend of consolidation in the domestic pharma sector. Mankind, Dr. Reddy’s, and Blackstone have evaluated BSV at different times, including before Advent's acquisition.
Are fears and panic around PSUs overblown? Sandip Sabharwal answers
Ideally, they should not be able to because like you rightly said, it is more commoditised. In fact, you look at the reason why did HDFC merge into HDFC Bank, because they realised that the margins are going to get squeezed and if they do not have a low-cost deposit franchise which supports the margin squeeze, that will become tougher.So, many of these housing finance companies sustain higher margins to develop financing, loan against property, etc, which are higher margin, but then also carry higher risk.
Mankind Pharma scouts for M&A deals to boost local branded biz
Mankind Pharma, the fourth-largest pharmaceutical company in India, led by Rajeev Juneja, is seeking mergers, acquisitions, and in-licensing deals to enhance its branded formulation business.
Stocks in the news: L&T, Sun Pharma, PNB, Zomato, Bank of India and REC
Online food delivery service provider Zomato plans to deliver food to its customers in record 10 minutes, following the footsteps of grocery delivery companies, Deepinder Goyal, the founder said in a tweet.
Bharat Serums acquires 26 pc stake in solar power firm AMP Energy C&I One
"This solar project resonates our belief in building a greener environment, judiciously using natural resources and renewable sources of energy while creating measurable social impact," Bharat Serums and Vaccines (BSV) MD and CEO Sanjiv Navangul said in a statement.
Call of Duty: ETILC members step up to shoulder Covid induced challenges
Leaders from the health industry are emphasizing that it is key to prepare employees for what lies ahead. Covid-19 will continue to remain a reality for the next year or so.
Amazon buys Perpule in all-cash deal
Amazon Technologies Inc., a subsidiary of the US-based retailer, acquired Perpule for Rs 107.6 crore in an all-cash deal.
India has scaled its medical infrastructure sufficiently: ET-ILC Forum
The lockdown gave the country and the medical fraternity enough time to prepare and scale infrastructure. The lockdown gave hospitals the time to ramp up ventilators, PPE and medical equipment, allowing India to move ahead with agility.
SC to examine if transactions regarding sale of BS-IV vehicles during lockdown genuine
The bench, also comprising Justices S A Nazeer and Indira Banerjee, noted that benefit of its March 27 order "cannot be taken two ways by making more sales during the period of lockdown and grace period of ten days further after March 31."
SBI moves NCLT to recover Rs 1.2k-cr Reliance Communications loans from Anil Ambani
SBI moved the NCLT under Section 97(3) of Insolvency and Bankruptcy Code (IBC), seeking its intervention to direct the insolvency board to nominate a resolution professional (RP). The bank is aiming to recover a sizeable amount from the personal guarantees made by Anil Ambani on loans to Reliance Communications, said a bank official.
PE Funds Advent, Kedaara in discussions to acquire Sequent
The founder promoters of Sequent, including serial entrepreneur Arun Kumar, KR Ravishankar and family, together hold about 56.5% in the listed entity, while PE investor Ascent Capital holds 5% stake. JP Morgan is running the sale process.
Advent set to buy controlling stake in Bharat Serum
Kotak PE and OrbiMed together that hold 23% stake in Mumbai-based biopharma company Bharat Serums and Vaccines (BSV) are exiting through this sale. The rest of the stake is with the Daftary family who are relinquishing control but will stay on as a minority partner, said people in the know. Advent will become the largest shareholder in the company.
Advent International emerges sole bidder for Bharat Serums
Kotak PE and OrbiMed together hold 23% stake in BSV. The rest of the stake is with the Daftary family.
Carlyle-Zydus and Advent join race to acquire Bharat Serums and Vaccines Ltd
They are up against domestic pharma companies Dr Reddy's Labs, Mankind & Goldman Sachs which have also made offers.
Domestic pharmaceutical players eye Bharat Serums acquisition
The two funds together hold a 23% stake and the remainder is with the Daftary family.
NCLT: Government must focus on creating infrastructure and make the tribunal self-sufficient
With numbers stacked up against the quick disposal of cases, the very purpose for which it was created, is the NCLT model set to fail?
NCLT approves Reliance Communications-Aircel merger, Brookfield deal
The NCLT also allowed Reliance Communications (RCOM) tower arm 51 per cent stake sale to Brookfield for Rs 11,000 crore.
NCLT to decide on RCom-Aircel merger on August 14
The merger could set the ball rolling for a sale of RCom’s stake in its tower unit to Canada’s Brookfield. Together, the deals could reduce its debt by even 60 per cent.
'Running against time' to close Aircel deal: Reliance Communications to NCLT
Representing the company, senior counsel told tribunal at a hearing that RCom is also in talks to address major lender China Development Bank’s apprehensions about the deal.
Load More